The mission of the Northern Indiana Cancer Research Consortium, Community Clinical Oncology Program (NICRC) is to promote community participation in National Cancer Institute (NCI) sponsored clinical trials. The NICRC focuses on accrual to both cancer treatment and cancer control clinical trials. Six area hospitals and a variety of physicians including oncologists, radiation oncologists, gynecologic oncologists, surgeons, specialists and primary care physicians have come together to support this endeavor. Through collaboration, these groups are able to build on each others'resources and outreach efforts in order to bring the best possible care to the community. When treating cancer, physicians have to consider numerous factors in addition to the best treatment options available for their patients. Quality of life, insurance, cost and time constraints are just some of the elements involved with cancer treatment. Receiving treatment close to home provides the patients with improved quality of life, decreased travel costs and additional time to spend with family and friends. Through the CCOP, the NICRC is able to provide patients with the best treatment options while allowing patients to receive treatment in their home communities. The science that is learned from participation in clinical trials is invaluable in the fight to cure cacer and the ability for patients to receive treatment close to home is priceless. In addition to treatig cancer, the NICRC is also dedicated to increasing public awareness about cancer and early detection. Through cancer control studies, the NICRC hopes to decrease the incidence and mortality of cancer in the local area.
Clinical trials provide scientific knowledge which in turn results in improved treatment options for patients. Enrolling patients to NCI sponsored clinical trials will increase the quality of health of the local community. Improved treatment options will also decrease mortality and the co-morbidities associated with cancer.
|Pradhan, Kamnesh R; Stump, Timothy E; Monahan, Patrick et al. (2015) Relationships among attention function, exercise, and body mass index: a comparison between young breast cancer survivors and acquaintance controls. Psychooncology 24:325-32|
|Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9|
|Werner, Benjamin; Gallagher, Robert E; Paietta, Elisabeth M et al. (2014) Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. Cancer Res 74:5386-96|
|Champion, Victoria L; Wagner, Lynne I; Monahan, Patrick O et al. (2014) Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. Cancer 120:2237-46|
|Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21|
|Burstein, Harold J; Cirrincione, Constance T; Barry, William T et al. (2014) Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women J Clin Oncol 32:3959-66|
|Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43|
|Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66|
|Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20|
|Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17|
Showing the most recent 10 out of 23 publications